Evaluation status available after sign-in
About the journal
Drugs in R&D is an open-access journal published by Adis, Springer Healthcare in United Kingdom, publishing in english. It is listed in DOAJ and MEDLINE and PUBMED according to the sources read. Declared publication charge: 2,690 EUR. Declared review time at DOAJ: 8 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Adis, Springer Healthcare
- ISSN
- 1174-5886 · 1179-6901
- Country
- United Kingdom
- Languages
- english
- Access
- Open access
- Declared publication charge
- 2,690 EUR
- Articles in DOAJ
- 209
- Declared review time
- 8 weeks
- Declared peer-review model
- other
- Official website
- https://www.springer.com/journal/40268
Index listings
- DOAJ · 2017-09-17
- MEDLINE · 1999-01-01
- PUBMED · 2011-09-01
- Indexing
- DOAJ · MEDLINE · PUBMED
- APC
- 2,690 EUR
- Declared review time (DOAJ)
- 8 weeks
- Actual review time (measured)
- 145 days received→accepted — computed from PubMed (n=27)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
209
Most recent article
2 months ago
Average review time (journal-declared via DOAJ)
8weeks
Works in OpenAlex
1377
Last recorded publication year
2025
Reported by OpenAlex in 2 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core
h-index
61
i10-index
455
From OpenAlex open data (CC0).
Editorial & policy13
- Last DOAJ review date
- 2026-03-17
- Added to DOAJ
- 2017-09-17
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSPortico
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 97%
- ORCID iDs in current deposits
- 67%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity3
- Alternate titles
- Drugs in research and developmentDrugs in research & development
- Source type
- journal
- NLM unique ID (PubMed)
- 100883647
Classification2
Subjects (DOAJ)
Medicine: Therapeutics. Pharmacology
LCC codes
RM1-950
Subject areas
- Pharmacogenetics and Drug Metabolism
- Cancer Treatment and Pharmacology
- Cancer Treatment and Pharmacology
- Pharmaceutical studies and practices
- Pharmacovigilance and Adverse Drug Reactions
- Statistical Methods in Clinical Trials
- Antibiotics Pharmacokinetics and Efficacy
- Biosimilars and Bioanalytical Methods
Show all subjects (75)
- Analytical Methods in Pharmaceuticals
- Diabetes Treatment and Management
- Advanced Drug Delivery Systems
- Antibiotics Pharmacokinetics and Efficacy
- HIV/AIDS drug development and treatment
- Antibiotics Pharmacokinetics and Efficacy
- Pharmaceutical studies and practices
- Biosimilars and Bioanalytical Methods
- Pharmacogenetics and Drug Metabolism
- Biosimilars and Bioanalytical Methods
- Pharmaceutical studies and practices
- Pharmacogenetics and Drug Metabolism
- Monoclonal and Polyclonal Antibodies Research
- Pain Management and Opioid Use
- Diabetes Treatment and Management
- Diabetes Treatment and Management
- Drug Solubulity and Delivery Systems
- HIV/AIDS drug development and treatment
- Pharmacological Effects and Toxicity Studies
- HIV/AIDS drug development and treatment
- Pharmacological Effects and Toxicity Studies
- Blood Pressure and Hypertension Studies
- Rheumatoid Arthritis Research and Therapies
- Pharmacology and Obesity Treatment
- Pharmacology and Obesity Treatment
- Medical research and treatments
- Diabetes Management and Research
- HIV Research and Treatment
- Chronic Lymphocytic Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Lipoproteins and Cardiovascular Health
- Anesthesia and Pain Management
- Drug-Induced Adverse Reactions
- Blood Pressure and Hypertension Studies
- Metabolism and Genetic Disorders
- Asthma and respiratory diseases
- Blood Pressure and Hypertension Studies
- Drug-Induced Adverse Reactions
- Treatment of Major Depression
- Metabolism and Genetic Disorders
- Pain Mechanisms and Treatments
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Treatments and Studies
- Pain Management and Opioid Use
- Asthma and respiratory diseases
- Pain Management and Opioid Use
- Rheumatoid Arthritis Research and Therapies
- Asthma and respiratory diseases
- Epilepsy research and treatment
- Atrial Fibrillation Management and Outcomes
- Rheumatoid Arthritis Research and Therapies
- Lipoproteins and Cardiovascular Health
- Lipoproteins and Cardiovascular Health
- Monoclonal and Polyclonal Antibodies Research
- Immunodeficiency and Autoimmune Disorders
- Monoclonal and Polyclonal Antibodies Research
- Immunodeficiency and Autoimmune Disorders
- Blood disorders and treatments
- Blood disorders and treatments
- Antimicrobial Resistance in Staphylococcus
- Epilepsy research and treatment
- Antimicrobial Resistance in Staphylococcus
- Epilepsy research and treatment
- Drug Solubulity and Delivery Systems
- Inflammatory mediators and NSAID effects
- Drug Solubulity and Delivery Systems
- Inflammatory mediators and NSAID effects
Keywords (DOAJ)
- pharmacology
- drug development
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
Loading community confirmations…
The journal's record in other sources:Web of Science MJLDOAJ